Selected article for: "early stage and patient admission"
Author: Jin, Xi; Lian, Jiang-Shan; Hu, Jian-Hua; Gao, Jianguo; Zheng, Lin; Zhang, Yi-Min; Hao, Shao-Rui; Jia, Hong-Yu; Cai, Huan; Zhang, Xiao-Li; Yu, Guo-Dong; Xu, Kai-Jin; Wang, Xiao-Yan; Gu, Jue-Qing; Zhang, Shan-Yan; Ye, Chan-Yuan; Jin, Ci-Liang; Lu, Ying-Feng; Yu, Xia; Yu, Xiao-Peng; Huang, Jian-Rong; Xu, Kang-Li; Ni, Qin; Yu, Cheng-Bo; Zhu, Biao; Li, Yong-Tao; Liu, Jun; Zhao, Hong; Zhang, Xuan; Yu, Liang; Guo, Yong-Zheng; Su, Jun-Wei; Tao, Jing-Jing; Lang, Guan-Jing; Wu, Xiao-Xin; Wu, Wen-Rui; Qv, Ting-Ting; Xiang, Dai-Rong; Yi, Ping; Shi, Ding; Chen, Yanfei; Ren, Yue; Qiu, Yun-Qing; Li, Lan-Juan; Sheng, Jifang; Yang, Yida
Title: Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms
  • Document date: 2020_3_24
    • ID: zph6r4il_37
    Snippet: This study has several limitations . First, it is better to obtain the outcomes and more detailed therapeutic responses in a cohort study of patients with COVID-19 with GI symptoms. Second, although the risk factors for the severe/critical type of COVID-19 were identified according to patient data on admission, there is still a lack of a predictive model for disease progression. Third, cytokine storm is common in coronavirus 28 and reported in a .....
    Document: This study has several limitations . First, it is better to obtain the outcomes and more detailed therapeutic responses in a cohort study of patients with COVID-19 with GI symptoms. Second, although the risk factors for the severe/critical type of COVID-19 were identified according to patient data on admission, there is still a lack of a predictive model for disease progression. Third, cytokine storm is common in coronavirus 28 and reported in a previous SARS-CoV-2 study 5 ; thus, it would be better if we could also detect cytokine changes in this study. Fourth, it will have more clinical relevance to propose an effective strategy for identifying patients with COVID-19 with GI symptoms who lack the typical symptoms such as fever and cough in the early stage. According to our experience, we should pay more attention to exposure history and family clustering during the screening process. Fifth, it would be meaningful to investigate the correlation between the viral genome and GI symptoms. Finally, since over 50% of SARS-CoV-2 was detected in the faeces according to one study, 29 the prevalence of viral RNA from faeces samples in patients with GI symptoms should be compared with those in patients without GI symptoms in the future. Moreover, because of the relatively low detection rate for virus in the stool (three of nine patients with COVID-19 positive in our hospital) and rare stool samples were re-tested for the virus in patients after their recovery in this study, it is difficult to evaluate the implications of faecal-oral transmission, so this needs further investigation.

    Search related documents:
    Co phrase search for related documents
    • attention pay and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • attention pay and cough fever: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • attention pay and critical type: 1, 2
    • attention pay and cytokine storm: 1, 2, 3
    • attention pay and detection rate: 1, 2
    • attention pay and disease progression: 1, 2, 3, 4, 5, 6
    • attention pay and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • attention pay and effective strategy: 1, 2
    • attention pay and exposure history: 1, 2, 3, 4, 5
    • clinical relevance and cohort study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical relevance and cough fever: 1, 2, 3, 4
    • clinical relevance and critical type: 1, 2, 3
    • clinical relevance and cytokine change: 1
    • clinical relevance and cytokine storm: 1, 2, 3
    • clinical relevance and detection rate: 1, 2, 3, 4, 5, 6
    • clinical relevance and disease progression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • clinical relevance and early stage: 1, 2, 3, 4, 5, 6
    • clinical relevance and effective strategy: 1, 2, 3, 4
    • clinical relevance and exposure history: 1, 2